Neuromuscular Diseases Clinical Trial
Official title:
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy"
In the last 10-15 years, a better understanding of the pathophysiology and molecular genetics of SMA has led to the emergence of previously unavailable pharmacological and genetic treatments.One of these new treatments, Nusinersen, targets SMN2, which is a slightly different copy of SMN1, and increases SMN protein levels. Preclinical studies have provided evidence that neuroprotection is strongly formed, with exercise significantly increasing motor neuron survival independent of SMN expression. In a limited number of clinical studies prior to Nusinersen treatment, it was reported that aerobic exercise training improved maximum oxygen uptake (VO2 max) without causing muscle damage, but still caused fatigue. The aim of this study is to determine the effect of aerobic exercise training on motor and respiratory functions, exercise capacity, fatigue and quality of life in SMA Type III patients who can walk and receive Nusinersen therapy. Twenty cases aged 10-50 years with genetically confirmed SMA diagnosis will be included in this study. The cases to be included in the study will be randomized into 2 groups as the training and control groups. In addition to the routine physiotherapy program, medium-intensity Aerobic Exercise Training will be given to the study group for 12 weeks. Before and 12 weeks after the training, the cases will be evaluated with the Six Minute Walking Test, Submaximal Exercise Test, SMN protein level, function and strength assessments, (FVC) value, fatigue and quality of life scales. In clinical trials, the supporting evidence for aerobic interventions in SMA is limited. Additional studies on aerobic intervention parameters (frequency, intensity and duration) are needed.The results of this study will determine the feasibility of aerobic exercise training and provide important guidance for the clinical management of SMA patients.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | September 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 50 Years |
Eligibility | Inclusion Criteria: - Have been diagnosed of SMA Type 3 confirmed by genetic analysis, - Between the ages of 10-50, - Being able to walk 25 m without assistive device Exclusion criteria: - Using research drugs for SMA treatment other than Nusinersen treatment, - Having a serious systemic disease that may prevent exercise, - Have had a lower extremity injury and/or surgery in the last 6 months, - To be applying a regular aerobic training program in the last 6 months |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul Faculty of Medicine, Department of Neurological Sciences | Istanbul | Fatih |
Lead Sponsor | Collaborator |
---|---|
Istanbul Medipol University Hospital | Istanbul University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional Capacity | Change from baseline functional capacity test at 12 weeks. Functional capacity will be assessed by the 6 minute walking test.The 6MWT, an objective evaluation of functional capacity, measures the maximum distance a person can walk in six minutes over a 25-meter linear course. | Baseline and 12 weeks | |
Secondary | Submaximal Exercise Test | Change from baseline Submaximal Exercise Capacity Test at 12 weeks. It will be evaluated by Incremental Submaximal Exercise Test. The tests will be performed by using an cycle ergometer. | Baseline and 12 weeks | |
Secondary | Pulmonary Function | Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 12 weeks. Pulmonary Function will be assessed by measuring forced expiratory vital capacity (FVC) as percent predicted for age and height. | Baseline and 12 weeks | |
Secondary | Motor Function | Change from baseline Hammersmith Functional Motor Scale, Expanded (HFMSE) at 12 weeks . The HFMSE is a 33-item scale designed for SMA type 2 and 3 patients.Items are scored on a 0-2 scale with a full score of 2 being normal without assistance, a partial score of 1 requiring a modified method but no assistance, and a zero score being unable to achieve the task without assistance. | Baseline and 12 weeks | |
Secondary | Motor Performance | Change from baseline 10 Meter Walk/Run Test at 12 weeks . This test measures the time it takes a subject to walk or run 10 meters as fast as possible without compromising the subject's safety. | Baseline and 12 weeks | |
Secondary | Balance and Mobility | Change from baseline Timed Up and Go Test (TUG) Test at 12 weeks The TUG test, which is a method to assess balance and mobility, measures the time it takes an individual to stand up from a chair, walk 3 meters, turn around, and sit down in the same chair.Ten seconds or less indicate normal mobility. | Baseline and 12 weeks | |
Secondary | Muscle strength | Change from baseline Manual Muscle Testing (MMT) at 12 weeks Manual muscle testing (MMT) augmented by hand held dynamometry (HHD) provides a comprehensive evaluation of muscle strength. | Baseline and 12 weeks | |
Secondary | Quality of Life in patients with neuromuscular disease | Change from baseline quality of life scale at 12 weeks The Pediatric quality of life™ 3.0 Neuromuscular Module (PedsQL™ 3.0 NMM) was designed to assess health-related quality of life (HRQoL) among aged 2-18 years with NMD.The scale consists of 25 items under 3 categories. .Items are scored on a Likert-type scale from 0 (never poses a problem) to 4 (always poses a problem). Scoring is between 0-100 .Higher scores from the Module indicate better health-related quality of life.For patients 18 years and older, The Short Form (SF-36), a widely used health-related quality of life measure. The Short Form (SF-36) Health Survey is a 36-item, patient-reported survey of patient health. | Baseline and at 12 weeks | |
Secondary | Fatigue | Change from baseline Fatigue Scale at 12 weeks.
The PedsQL Multidimensional Fatigue Scale comprises parallel child self-report and parent proxy-reportformats. A 5-point response scale is utilized across child and a dolescent self-report for ages 8-18 and paren proxy-report . Items are reverse scored and linearly transformed to a 0-100 scale.Higher PedsQL Multidimen-sional Fatigue Scale scores indicate better HRQOL. The Fatigue Severity Scale (FSS) is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in adult patients with a variety of disorders .A self-report scale of nine items about fatigue,The higher the score, the more severe the fatigue is and the more it affects the person's activities. |
Baseline and 12 weeks | |
Secondary | Functional Lower Extremity Strength, | Change from baseline Five Times Sit to Stand Test at 12 weeks.
The five Times Sit to Stand Test( 5XSS) scoring is based on the amount of time a patient is able to transfer from a seated to a standing position and back to sitting five times. The lower the time to complete the test the better the outcome of the test. The Minimal Detectable Change(MDC) time for the test is within 3.6 to 4.2 second and Minimal clinically important difference (MCID) is 2.3 seconds. |
Baseline and 12 weeks | |
Secondary | Evaluation of SMN protein levels in blood biochemistry | Change from baseline SMN protein levels at 12 weeks. The response of patients' SMN protein levels to exercise will be evaluated before and after 12 weeks of training. | Baseline and 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT04435093 -
Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.
|
||
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT05785546 -
Elaboration of a Pronostic Score of Changes on Wheelchair's Seating System
|
||
Completed |
NCT01313325 -
Hippotherapy to Improve the Balance of Children With Movement Disorders
|
N/A | |
Recruiting |
NCT04098094 -
Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
|
||
Active, not recruiting |
NCT05070624 -
The Peer Support Study
|
N/A | |
Completed |
NCT04729920 -
Home Use of Mechanical Insufflation/Exsufflation Devices in Neuromuscular Diseases
|
||
Recruiting |
NCT04581577 -
Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders
|
||
Completed |
NCT06428864 -
Effect of the Use of a 3D Scanner Application on a Smartphone to Mold Garchois Orthotic Device in Neuromuscular Diseases Patients With Scoliosis
|
||
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Completed |
NCT05353738 -
Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy
|
||
Recruiting |
NCT04541602 -
Detection of Neuromuscular Complications in Critically Ill Patients
|
||
Completed |
NCT03394859 -
Electronic Medical Records and Genomics (eMERGE) Phase III
|
||
Enrolling by invitation |
NCT05099107 -
Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment
|
N/A | |
Completed |
NCT05070910 -
NDT Effectiveness Study
|
N/A | |
Recruiting |
NCT04100993 -
Multisystem and Autonomic Complications of NMD on Long-term NIV
|
||
Recruiting |
NCT04986059 -
Effects of Pre-event Massage on Muscle Activity
|
N/A | |
Completed |
NCT01022931 -
Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva
|
N/A | |
Terminated |
NCT03353064 -
Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure
|
N/A |